Olema Oncology
Michelle Bolner, PhD, has a diverse work experience in the field of medical affairs and scientific communications. Michelle started their career at MD Anderson Cancer Center as a Graduate Research Assistant in 2008 and later moved on to roles at ALK, Agendia, and finally Olema Oncology, where they currently serve as the Director of Medical Affairs & Scientific Communications. Their roles have ranged from Medical Science Liaison to Scientific Advisor, showcasing their expertise in the healthcare industry.
Michelle Bolner, PhD earned their Bachelor of Science degree in Biology from Baylor University in 2008. Michelle then went on to complete a Master's degree in Biomedical Sciences, General at UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences in 2012. Michelle later obtained their Doctor of Philosophy (PhD) in Epigenetics and Molecular Carcinogenesis from the same institution in 2015.
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.